Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML335 是一种有效的 TREK-1和 TREK-2选择性激活剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 237 | 现货 | ||
5 mg | ¥ 547 | 现货 | ||
10 mg | ¥ 913 | 现货 | ||
25 mg | ¥ 1,630 | 现货 | ||
50 mg | ¥ 2,420 | 现货 | ||
100 mg | ¥ 3,590 | 现货 | ||
500 mg | ¥ 7,760 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 552 | 现货 |
产品描述 | ML335 is a selective activator of TREK-1 and TREK-2. |
体外活性 | Xenopus oocyte two-electrode voltage-clamp measurements show that ML335 and ML402 activate K2P2.1 and K2P10.1 but not K2P4.1 (14.3±2.7?μM, K2P2.1-ML335; 13.7±7.0?μM, K2P2.1-ML402; 5.2±0.5?μM, K2P10.1-ML335; and 5.9±1.6?μM, K2P10.1-ML402). Swapping the Lys271 equivalent between K2P2.1 and K2P4.1 results in a clear phenotype reversal for ML335 and M402 activation. ML335 and ML402 activate K2P2.1 in HEK293 cells similar to their effects in Xenopus oocytes (5.2±0.8?μM and 5.9±1.6?μM for ML335 and ML402, respectively (n≥3)) |
细胞实验 | Mouse K2P2.1, human K2P4.1, and mutants are expressed from a previously described pIRES2-EGFP vector in HEK293T cells (ATTC). 70% confluent cells are transfected (in 35-mm diameter wells) with LipofectAMINE 2000 for 6?h, and plated onto coverslips coated with Matrigel. Effects of ML335, ML402 and arachidonic acid on K2P2.1 current at 0?mV are measured by whole-cell patch-clamp experiments 24?h after transfection. Acquisition and analysis are performed using pCLAMP9 and an Axopatch 200B amplifier. Pipette resistance ranges from 1 to 1.5?MΩ. Pipette solution contains the following: 145?mM KCl, 3?mM MgCl2, 5?mM EGTA and 20?mM HEPES (pH 7.2 with KOH). Bath solution contains the following: 145?mM NaCl, 5?mM KCl, 1?mM CaCl2, 3?mM MgCl2 and 20?mM HEPES (pH 7.4 with NaOH). K2P2.1 currents are elicited by a 1?s ramp from -100 to +50?mV from a -80?mV holding potential. After stabilization of the basal current, ML335 and ML402 are perfused at 200?mL per hour until potentiation is stably reached[1]. |
分子量 | 373.25 |
分子式 | C15H14Cl2N2O3S |
CAS No. | 825658-06-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 155 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ML335 825658-06-8 Membrane transporter/Ion channel Potassium Channel ML-335 ML 335 KcsA Inhibitor inhibit inhibitor